Please use this identifier to cite or link to this item: https://hdl.handle.net/11000/31134
Full metadata record
DC FieldValueLanguage
dc.contributor.authorGarcía Ayllón, María Salud-
dc.contributor.authorMoreno Pérez, Óscar-
dc.contributor.authorGarcía Arriaza, Juan-
dc.contributor.authorRamos Rincón, José Manuel-
dc.contributor.authorCortés Gómez, María Ángeles-
dc.contributor.authorBrinkmalm, Gunnar-
dc.contributor.authorAndrés, Mariano-
dc.contributor.authorLeón Ramírez, José Manuel-
dc.contributor.authorBoix Martínez, Vicente-
dc.contributor.authorGil, Joan-
dc.contributor.authorZetterberg, Henrik-
dc.contributor.authorEsteban, Mariano-
dc.contributor.authorMerino de Lucas, Esperanza-
dc.contributor.otherInstituto de Neurocienciases_ES
dc.contributor.otherDepartamentos de la UMH::Medicina Clínicaes_ES
dc.date.accessioned2024-02-06T06:44:56Z-
dc.date.available2024-02-06T06:44:56Z-
dc.date.created2021-08-
dc.identifier.citationTHE FASEB JOURNAL 2021 Aug;35(8):e21745es_ES
dc.identifier.issn0892-6638-
dc.identifier.issn1530-6860-
dc.identifier.urihttps://hdl.handle.net/11000/31134-
dc.description.abstractStudies are needed to identify useful biomarkers to assess the severity and prognosis of COVID-19 disease, caused by severe acute respiratory syndrome coronavirus (SARS-CoV-2) virus. Here, we examine the levels of various plasma species of the SARS-CoV-2 host receptor, the angiotensin-converting enzyme 2 (ACE2), in patients at different phases of the infection. Human plasma ACE2 species were characterized by immunoprecipitation and western blotting employing antibodies against the ectodomain and the C-terminal domain, using a recombinant human ACE2 protein as control. In addition, changes in the cleaved and full-length ACE2 species were also examined in serum samples derived from humanized K18-hACE2 mice challenged with a lethal dose of SARS-CoV-2. ACE2 immunoreactivity was present in human plasma as several molecular mass species that probably comprise truncated (70 and 75 kDa) and full-length forms (95, 100, 130, and 170 kDa). COVID-19 patients in the acute phase of infection (n = 46) had significantly decreased levels of ACE2 full-length species, while a truncated 70-kDa form was marginally higher compared with non-disease controls (n = 26). Levels of ACE2 full-length species were in the normal range in patients after a recovery period with an interval of 58-70 days (n = 29), while the 70-kDa species decreased. Levels of the truncated ACE2 species served to discriminate between individuals infected by SARS-CoV-2 and those infected with influenza A virus (n = 17). In conclusion, specific plasma ACE2 species are altered in patients with COVID-19 and these changes normalize during the recovery phase. Alterations in ACE2 species following SARS-CoV-2 infection warrant further investigation regarding their potential usefulness as biomarkers for the disease process and to asses efficacy during vaccination.es_ES
dc.formatapplication/pdfes_ES
dc.format.extent16es_ES
dc.language.isoenges_ES
dc.publisherWiley [Commercial Publisher]es_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectACE2es_ES
dc.subjectbiomarkeres_ES
dc.subjectCOVID- 19es_ES
dc.subjectplasmaes_ES
dc.subjectSARS- CoV- 2es_ES
dc.subject.otherCDU::6 - Ciencias aplicadas::61 - Medicina::616 - Patología. Medicina clínica. Oncologíaes_ES
dc.titlePlasma ACE2 species are differentially altered in COVID-19 patientses_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.relation.publisherversionhttps://doi.org/10.1096/fj.202100051Res_ES
Appears in Collections:
Artículos Medicina Clínica


Thumbnail

View/Open:
 Plasma ACE2 species are differentially altered in COVID-19.pdf

1,21 MB
Adobe PDF
Share:


Creative Commons ???jsp.display-item.text9???